1. Acknowledgement to Referees

   Acknowledgement to Referees 03 November 2022 Pages: 611 - 614

2. Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study

   • Michelino De Laurentiis
   • Roberta Caputo
   • Claudio Zamagni

   Original Research Article Open access 24 September 2022 Pages: 615 - 625

   

3. Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients

   • Mahmoud Mohammadi
   • Thekla M. Jansen-Werkhoven
   • Hans Gelderblom

   Original Research Article Open access 14 November 2022 Pages: 627 - 634

   

4. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer

   • Gianluca Arrichiello
   • Alessandra Perrone
   • Teresa Troiani

   Original Research Article Open access 14 October 2022 Pages: 635 - 642

   

5. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis

   • Takashi Niizeki
   • Takayuki Tokunaga
   • Yasuhito Tanaka

   Original Research Article Open access 22 October 2022 Pages: 643 - 653

   

6. Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies

   • Kyle Dunton
   • Gerard Vondeling
   • Abby Paine

   Original Research Article Open access 07 November 2022 Pages: 655 - 663

   

7. Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?

   • Suji Udayakumar
   • Sasha Thomson
   • Kelvin K. W. Chan

   Original Research Article 05 October 2022 Pages: 665 - 674

   

8. Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study

   • Assya Akli
   • Nicolas Girard
   • Etienne Giroux-Leprieur

   Original Research Article 21 September 2022 Pages: 675 - 682

   

9. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene

   • Alessa Fischer
   • Lorenz Bankel
   • Alessandra Curioni-Fontecedro

   Original Research Article Open access 22 September 2022 Pages: 683 - 694

   

10. Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors

    • Yuta Doi
    • Hiroaki Tagaya
    • Kentaro Semba

    Original Research Article 06 October 2022 Pages: 695 - 707

    

11. Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams

    • Neal D. Shore
    • Alicia K. Morgans
    • Matthew Abramowitz

    Therapy in Practice Open access 18 November 2022 Pages: 709 - 725

    

12. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer

    • Arnold Lee

    Adis Drug Evaluation Open access 31 October 2022 Pages: 727 - 733